Medical Condition News

RSS

AbbVie reports results from venetoclax Phase 2 clinical trial in AML at ASH 2014

AbbVie presented during an oral presentation at the American Society of Hematology's 56th Annual Meeting new results from a Phase 2 study of investigational compound venetoclax (ABT-199/GDC-0199) in patients with acute myelogenous leukemia (AML). AML is an aggressive and deadly type of blood cancer, in which the body produces too many of a specific type of white blood cell (myeloblast), which can crowd out healthy blood cells.

8 Dec 2014

Continuous glucose monitoring (CGM) mobile communications: an interview with Jorge Valdes

Type 1 diabetes is a complex condition to manage. It requires continuous, around the clock monitoring of blood glucose levels, which change repeatedly throughout the day and night.

7 Dec 2014

Novel targeted therapies and treatment combinations for leukemia

Recognizing that leukemia cannot be conquered with a "one-size-fits-all" approach, researchers are pursuing novel targeted therapies and combinations of existing treatment regimens with new agents for patient populations with historically poor prognoses, according to data presented today during the 56th American Society of Hematology Annual Meeting and Exposition.

7 Dec 2014

Novo Nordisk reports positive data from Novoeight phase 3 study in people with haemophilia A

Today, Novo Nordisk announced a new analysis of phase 3 data demonstrating people with haemophilia A who had the highest annualised bleeding rate (ABR) during initial treatment with Novoeight (Antihemophilic Factor [Recombinant]) showed the largest reduction in bleeding over the duration of treatment.

From Novo Nordisk 7 Dec 2014

Breakthrough therapy shows promise in resistant forms of Hodgkin lymphoma

A therapy that liberates the immune system to attack cancer cells drove Hodgkin lymphoma (HL) into complete or partial remission in fully 87 percent of patients with resistant forms of the disease who participated in an early-phase clinical trial, investigators at Dana-Farber Cancer Institute and partnering institutions report in a study published today in the New England Journal of Medicine and simultaneously presented at the annual meeting of the American Society of Hematology in San Francisco.

7 Dec 2014

Pembrolizumab shows promising results in patients with classical Hodgkin Lymphoma

Merck, known as MSD outside of Canada and the United States, announced today early study findings demonstrating that patients treated with pembrolizumab, the company's investigational anti-PD-1 cancer therapy, achieved an overall response rate of 66 percent, as assessed by International Harmonization Project response criteria (n=19/29: 95% CI, 46-82).

7 Dec 2014

Emerging strategies to boost healthy RBCs may reduce burden of anemia linked to blood disorders

Emerging treatment approaches may reduce the burden of anemia associated with blood disorders by enhancing production of healthy red blood cells, according to data presented today at the 56th American Society of Hematology Annual Meeting and Exposition.

7 Dec 2014

Researchers identify new targets for future CLL therapies

Chronic lymphocytic leukemia (CLL) is among the most frequent leukemias affecting adults in Western countries. It usually occurs in older patients, does not cause any symptoms for a long time and is often only discovered by accident. Despite treatment, relapses frequently occur. The immunologists Dr. Kristina Heinig and Dr. Uta Höpken (Max Delbrück Center for Molecular Medicine, MDC, Berlin-Buch) and the hematologist Dr. Armin Rehm (MDC and Charité - Universitätsmedizin Berlin) have now discovered why this is so.

7 Dec 2014

Nivolumab drug highly effective for Hodgkin's lymphoma

A phase I clinical trial of nivolumab found that the immune-boosting drug is a highly effective therapy for Hodgkin's lymphoma. The multi-institution study, led by Mayo Clinic, indicated that the drug was safe and led to an 87 percent response rate in patients who had failed on other treatments.

7 Dec 2014

Study shows link between cardiac abnormalities, sudden unexpected death in epilepsy

Groundbreaking findings describing the link between cardiac abnormalities and sudden unexpected death in epilepsy (SUDEP) will be presented at the American Epilepsy Society's Annual Meeting in December.

7 Dec 2014

New study explores reliability of optogenetics as method of intervention of temporal lobe seizures

Optogenetics is one of the hottest tools in biomedical research today, a method that uses gene therapy to deliver light-sensitive proteins into specific cells. This new tool allows researchers to interact with a single cell or a network of cells with exquisite precision. Whereas imaging and other technologies allow researchers to watch the brain in action, optogenetics enables them to influence those actions.

7 Dec 2014

New treatment combinations improve outcomes for vulnerable patient with hard-to-treat disease

New treatment combinations and targeted therapies for lymphoma and multiple myeloma are improving outcomes for vulnerable patient populations with hard-to-treat disease, according to studies presented today at the 56th American Society of Hematology Annual Meeting and Exposition.

7 Dec 2014

Findings may guide doctors to choose better therapies for patients with myeloma

The "molecular mail" sent by multiple myeloma cells provides clues to how well patients with the disease are likely to respond to treatment, according to a study being presented at the annual meeting of the American Society of Hematology by researchers at Dana-Farber Cancer Institute.

7 Dec 2014

Novel treatments show promising results in patients with different hematologic disorders

In recent years, a number of scientific breakthroughs have led to the development of drugs that unleash the power of the immune system to recognize and attack cancer. Studies presented today at the 56th Annual Meeting of the American Society of Hematology highlight the enormous potential these novel treatments have for patients with a variety of hematologic disorders.

7 Dec 2014

Study: Key protein may help prevent tumor growth, promote wound healing

A key protein may represent a new way to use the immune system to speed healing and counter inflammatory, infectious and autoimmune diseases, according to study led by researchers at the Icahn School of Medicine at Mount Sinai and published in the December issue of Cell Reports.

7 Dec 2014

BUSM's Carmela Abraham receives 2014 Massachusetts Neuroscience Consortium Award

Carmela Abraham, PhD, professor of biochemistry and pharmacology at Boston University School of Medicine, was one of six recipients of this year's Massachusetts Neuroscience Consortium Award out of nearly 60 applicants. The grant was awarded to her for her work on multiple sclerosis and the role of the life extension protein Klotho in the limited repair of white matter in the disease.

7 Dec 2014

Three-drug combination produces better results in multiple myeloma patients

In the treatment of multiple myeloma, the addition of carfilzomib to a currently accepted two-drug combination produced significantly better results than using the two drugs alone, according to a worldwide research team led by investigators from Mayo Clinic.

7 Dec 2014

Adding maintenance therapy after transplant can improve outcomes in Hodgkin lymphoma patients

In a late-stage clinical trial, Hodgkin lymphoma (HL) patients who received brentuximab vedotin (BV) post-transplant lived longer without disease progression than patients who received only supportive care. This is the first time a study has demonstrated that adding a maintenance therapy after transplant can improve outcomes.

7 Dec 2014

Researchers reveal that genetic mutations may cause more cases of ALS

Genetic mutations may cause more cases of amyotrophic lateral sclerosis (ALS) than scientists previously had realized, according to researchers at Washington University School of Medicine in St. Louis and Cedars-Sinai Medical Center in Los Angeles. The scientists also showed that the number of mutated genes influences the age when the fatal paralyzing disorder first appears.

7 Dec 2014

MorphoSys, Xencor announce final results from MOR208 Phase 1/2a trial in patients with CLL/SLL

MorphoSys AG and Xencor Inc. today announced the publication of final results of a Phase 1/2a trial evaluating MOR208 (formerly XmAb5574) in patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic leukemia (CLL/SLL).

7 Dec 2014

Medical Condition News

AbbVie reports results from venetoclax Phase 2 clinical trial in AML at ASH 2014

Continuous glucose monitoring (CGM) mobile communications: an interview with Jorge Valdes

Novel targeted therapies and treatment combinations for leukemia

Novo Nordisk reports positive data from Novoeight phase 3 study in people with haemophilia A

Breakthrough therapy shows promise in resistant forms of Hodgkin lymphoma

Pembrolizumab shows promising results in patients with classical Hodgkin Lymphoma

Emerging strategies to boost healthy RBCs may reduce burden of anemia linked to blood disorders

Researchers identify new targets for future CLL therapies

Nivolumab drug highly effective for Hodgkin's lymphoma

Study shows link between cardiac abnormalities, sudden unexpected death in epilepsy

New study explores reliability of optogenetics as method of intervention of temporal lobe seizures

New treatment combinations improve outcomes for vulnerable patient with hard-to-treat disease

Findings may guide doctors to choose better therapies for patients with myeloma

Novel treatments show promising results in patients with different hematologic disorders

Study: Key protein may help prevent tumor growth, promote wound healing

BUSM's Carmela Abraham receives 2014 Massachusetts Neuroscience Consortium Award

Three-drug combination produces better results in multiple myeloma patients

Adding maintenance therapy after transplant can improve outcomes in Hodgkin lymphoma patients

Researchers reveal that genetic mutations may cause more cases of ALS

MorphoSys, Xencor announce final results from MOR208 Phase 1/2a trial in patients with CLL/SLL

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Latest News